Hematological disorders after salvage PARPi treatment for ovarian cancer: Cytogenetic and molecular defects and clinical outcomes

Inhibitors of poly(ADP‐ribose) polymerase (PARPi) are increasingly employed as salvage therapy in epithelial ovarian cancer (EOC), but cytotoxic drug exposure along with PARP inhibition may favor development of hematological disorders. In our study, of 182 women with EOC treated with PARPi, 16 (8.7%...

ver descrição completa

Detalhes bibliográficos
Autores principales: Todisco, Elisabetta, Gigli, Federica, Ronchini, Chiara, Amato, Viviana, Sammassimo, Simona, Pastano, Rocco, Parma, Gabriella, Lapresa, Maria Teresa, Bertolini, Francesco, Corsini, Chiara, Gregato, Giuliana, Poletti, Claudia, Pelicci, Pier Giuseppe, Alcalay, Myriam, Colombo, Nicoletta, Tarella, Corrado
Formato: Online Artigo Texto
Idioma:English
Publicado em: John Wiley & Sons, Inc. 2022
Assuntos:
Cancer Therapy and Prevention
Acesso em linha:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796966/
https://www.ncbi.nlm.nih.gov/pubmed/35695283
http://dx.doi.org/10.1002/ijc.34162

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796966/
https://www.ncbi.nlm.nih.gov/pubmed/35695283
http://dx.doi.org/10.1002/ijc.34162

Registos relacionados